Lupin says working on 10 promising lead molecules

Lupin has always been very shy in discussing their drug discovery pipeline. However, in an exclusive interview with CNBC-TV18, Dr Kamal Sharma, said that the company is excited about the R&D pipeline, which has 10 lead molecules, and could be potential out-licencing targets by next year.

Kamal Sharma, Managing Director, Lupin says "After having restructured now, we call it New Drug Discovery Research or NDDR. We have some very promising work going on. Whatever I get to know from my scientists, I think they are extremely excited about the work they are doing."
He further says, "As regards to the news in the market is concerned, maybe you have to wait a year. Some of these targets will definitely be very worthy targets for licensing out. That's our phase one of NDDR that we will be licensing them out."